Inverse probability weighting to estimate causal effect of a singular phase in a multiphase randomized clinical trial for multiple myeloma

Table 3 Estimated inverse probability of treatment weight (IPTW) and stabilized inverse probability of treatment weight (SIPTW) of starting 1^st ASCT (A), of starting consolidation therapy (B) and total product (TSIPTW) (C), respectively

	Mean ± Standard Deviation	Range
Starting 1^st ASCT (A)
IPTW	2.00 ± 2.75	1.03–20.88
SIPTW	1.00 ± 0.21	0.29–2.62
Starting Consolidation Therapy (B)
IPTW	1.87 ± 2.52	1.00–31.75
SIPTW	1.00 ± 0.37	0.43–5.79
Total Product (C)
IPTW	2.99 ± 3.74	1.09–34.67
SIPTW	1.00 ± 0.42	0.29–5.53

ISSN: 1471-2288